More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Ethics Board Approval Granted for Lexaria Receives Ethics Board Approval for 12-Week Phase 1b DehydraTECH GLP-1 Study in ...

Study estimates 136.8 million U.S. adults are eligible for semaglutide, a popular therapy for diabetes, weight loss, and cardiovascular disease.

The Company is also announcing that clinical test article manufacturing for all planned Study arms has already been completed. This includes production for the four planned DehydraTECH formulation ...

Here’s what to know about Rybelsus semaglutide tablets versus injections for weight loss and diabetes. This medication doesn’t have FDA approval for weight loss, but some healthcare providers ...

DehydraTECH clinical test article manufacturing has been completed KELOWNA, BC / ACCESSWIRE / November 13, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global i ...

Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

On World Diabetes Day, we talk to experts about the causes, symptoms and treatment of type 1 and 2 diabetes, and changes that ...

A surprise amount of Brits say they would take anti-obesity drugs if they were given to them for free on the ...

That means compounded versions of semaglutide – the active ingredient in Novo Nordisk's Ozempic and Rybelsus for diabetes and obesity therapy Wegovy – are already in the market. While Novo ...